Coronavirus (COVID-19) Preparedness Information Learn More
Clark Memorial Receives Initial Doses of Monoclonal antibody treatment for COVID-19
November 13, 2020
Clark Memorial Health is excited to share the news that our hospital received initial doses of bamlanivimab, a monoclonal antibody treatment for COVID-19, only one day after it received emergency use authorization (EUA) from the Food and Drug Administration (FDA). The therapy is now being allocated by the U.S. Department of Health and Human Services (HHS) in partnership with state health agencies. As Governor Holcomb shared on Wednesday, the drug was developed by Indianapolis-based pharmaceutical company Eli Lilly to help treat non-hospitalized patients with a mild or moderate case of COVID-19. We are proud to share that we utilized this therapy with qualifying patients since receiving our allocated doses on Nov. 10, making us the first in the country to administer this drug post-EUA.
Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful viruses. Eli Lilly’s monoclonal antibody therapy for COVID-19, in particular, is designed to help block the SARS-CoV-2 virus and prevent the virus from further infecting healthy cells.
Administered intravenously, this innovative treatment is designed to help lessen the severity of COVID-19 in individuals who are COVID-19-positive and are at risk for developing a severe form of the disease. Patients must meet specific clinical criteria, including having a lab-confirmed case of COVID-19 that is mild or moderate; having underlying health conditions or > 65 years of age; and being stable enough not to require hospitalization. We would like to emphasize to our community that this is a limited, investigational treatment that is being carefully allocated by the Indiana State Department of Health (ISDH) and requires an order from your provider.
Our providers will continue to carefully monitor patients who have received this therapy and will evaluate other COVID-19-positive individuals for whom this therapy may be effective, following strict criteria for administration.Offering this treatment is an important step forward in helping prevent the most at-risk patients from being hospitalized due to COVID-19. We continue to be deeply committed to finding new ways to serve our community during the pandemic and advance our mission of Making Communities Healthier.